Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2016

01-09-2016 | Research Article

SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma

Authors: Z. Zhao, J. Ma, K. Wu, L. Chen, J. Yu, W. Hu, K. Zhang

Published in: Clinical and Translational Oncology | Issue 9/2016

Login to get access

Abstract

Background

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignant tumor of the liver with a poor prognosis. Upregulation of special AT-rich sequence-binding protein 1 (SATB1) promotes tumor progression. However, little is known about the role of SATB1 in ICC tumorigenesis.

Methods

We firstly investigated the expression of SATB1 in 88 cases of ICC by immunohistochemistry (IHC), QRT-PCR, and western blot. Meanwhile, we constructed stably knockdown (shRNA) of SATB1 in ICC cell lines to evaluate the effects of SATB1 on the ability of cell proliferation and invasion by MTT and transwell invasion assay.

Results

Our result showed that SATB1 was overexpressed in ICC tissues samples. Knockdown of SATB1 could inhibit ICC cell proliferation, and suppress ICC cell invasion of ICC cell lines. In addition, the depletion of SATB1 expression suppressed the MYC levels in vitro.

Conclusions

Our results highlight the significance of SATB1 in ICC and suggest that SATB1 could be a promising therapy target and a potential biomarker for prognosis in ICC patients.
Literature
1.
2.
Farley DR, Weaver AL, Nagorney DM. “Natural history” of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc. 2005;70:425–9.CrossRef
3.
Sanada Y, Kawashita Y, Okada S, Azuma T, Matsuo S. Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma. World J Gastrointest Pathophysiol. 2014;5:188–99.PubMedPubMedCentral
4.
Andersen JB. Molecular pathogenesis of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2015;22(2):101–13.CrossRefPubMed
5.
Galande S, Dickinson LA, Mian IS, Sikorska M, Kohwi-Shigematsu T. SATB1 cleavage by caspase 6 disrupts PDZ domain-mediated dimerization, causing detachment from chromatin early in T-cell apoptosis. Mol Cell Biol. 2001;21:5591–604.CrossRefPubMedPubMedCentral
6.
Han B, Luan L, Xu Z, Wu B. Expression and biological roles of SATB1 in human bladder cancer. Tumour Biol. 2013;34:2943–9.CrossRefPubMed
7.
Mao L, Yang C, Wang J, Li W, Wen R, Chen J, et al. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 2013;11:111.CrossRefPubMedPubMedCentral
8.
Li QQ, Chen ZQ, Xu JD, Cao XX, Chen Q, Liu XP, et al. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci. 2010;101:80–6.CrossRefPubMed
9.
Alvarez JD, Yasui DH, Niida H, Joh T, Loh DY, Kohwi-Shigematsu T. The MAR-binding protein SATB1 orchestrates temporal and spatial expression of multiple genes during T-cell development. Genes Dev. 2000;14:521–35.PubMedPubMedCentral
10.
Ahlfors H, Limaye A, Elo LL, Tuomela S, Burute M, Gottimukkala KV. SATB1 dictates expression of multiple genes including IL-5 involved in human T helper cell differentiation. Blood. 2010;116:1443–53.CrossRefPubMedPubMedCentral
11.
Notani D, Gottimukkala KP, Jayani RS, Limaye AS, Damle MV, Mehta S, et al. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol. 2010;8:e1000296.CrossRefPubMedPubMedCentral
12.
Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003;34:42–51.CrossRefPubMed
13.
Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002;419:641–5.CrossRefPubMed
14.
Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187–93.CrossRefPubMed
15.
Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al. Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL J Oto-Rhinolaryngol Relat Spec. 2010;72:1–5.CrossRef
16.
Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS: acta pathologica, microbiologica, et immunologica. Scandinavica. 2010;118:855–63.
17.
Ren J, Jin F, Yu Z, Zhao L, Wang L, Bai X, et al. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol. 2013;34:3945–58.CrossRefPubMed
18.
Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis. 2010;13:311–5.CrossRefPubMed
19.
Chen CH, Shen J, Lee WJ, Chow SN. Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer. Int J Gynecol Cancer. 2005;15:878–83.CrossRefPubMed
20.
Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2010;2:16–20.PubMedPubMedCentral
Metadata
Title
SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma
Authors
Z. Zhao
J. Ma
K. Wu
L. Chen
J. Yu
W. Hu
K. Zhang
Publication date
01-09-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1449-x

Other articles of this Issue 9/2016

Clinical and Translational Oncology 9/2016 Go to the issue

Research Article

Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells

Review Article

The emerging role of Snail1 in the tumor stroma

Research Article

Paediatric tumour boards in Spain: a national survey

Research Article

Quality of life in patients treated by adjuvant radiotherapy for endometrial and cervical cancers: correlation with dose–volume parameters

Review Article

Braf V600E mutation in melanoma: translational current scenario

Research Article

Patterns and management of distant failure in locally advanced rectal cancer: a cohort study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits